Pooling data from 12 studies, tirzepatide produced nearly 5 kg more weight loss and was 2–3 times more likely to help patients reach major weight loss milestones compared to semaglutide.
4.76 kg moreAdditional weight loss with tirzepatide over semaglutide across 12 pooled studies
What the researchers found
Across 12 studies, tirzepatide produced significantly greater weight loss than semaglutide. Tirzepatide users lost an additional 4.61% body weight (95% CI: -6.03 to -3.20, p<0.00001) and 4.76 kg more (95% CI: -6.09 to -3.42, p<0.00001) than semaglutide users.
Tirzepatide users were also significantly more likely to reach key weight loss milestones: 1.52× more likely to lose ≥5%, 2.33× more likely to lose ≥10%, 2.82× more likely to lose ≥15%, and 2.28× more likely to lose ≥20% of body weight. All comparisons were statistically significant.
Why it matters
This is the first meta-analysis to directly compare the two most prominent weight loss peptide drugs head-to-head. The consistent advantage of tirzepatide across all weight loss thresholds provides the strongest pooled evidence to date for choosing between these therapies.
The numbers in context
12 studies · MD -4.61% body weight · MD -4.76 kg · OR 2.82 for ≥15% loss · OR 2.28 for ≥20% loss · p<0.00001 for most comparisons
How the study worked
Systematic review and meta-analysis searching Europe PMC, Medline, Scopus, and Cochrane Library for RCTs and observational studies directly comparing tirzepatide and semaglutide for weight loss. Pooled analyses used random-effects models to calculate mean differences and odds ratios with 95% confidence intervals. Heterogeneity was assessed using I² statistics.
Who was studied
Adults with overweight or obesity across 12 studies (RCTs and observational)
What this study cannot tell us
High heterogeneity (I²=87–97%) across all outcomes suggests substantial variability between studies in populations, doses, and follow-up periods. The inclusion of observational studies alongside RCTs limits causal inference. The analysis did not assess safety profiles, cost-effectiveness, or long-term outcomes beyond the study periods.
How to read the evidence
As a systematic review and meta-analysis pooling 12 studies, this represents a high level of evidence synthesis. However, high heterogeneity (I²>87% across outcomes) and inclusion of observational studies temper the certainty somewhat.
When this study was published
Published in 2026, this is the most current meta-analysis comparing these two leading weight loss peptide drugs, incorporating the latest available trial and real-world data.
The bigger picture
The tirzepatide vs. semaglutide comparison is the central question in obesity pharmacotherapy today. This meta-analysis provides the most comprehensive pooled evidence to date favoring tirzepatide's dual GIP/GLP-1 mechanism for weight reduction. However, treatment choice also depends on safety, tolerability, cost, and availability — factors this analysis did not address.
Questions still open
- Does tirzepatide's weight loss advantage translate to better cardiovascular and metabolic outcomes long-term?
- How do side effect profiles compare at equivalent weight-loss-producing doses?
- Will cost and insurance coverage differences offset the clinical advantage of tirzepatide?
Common questions
How much more weight do people lose on tirzepatide vs. semaglutide?
Does this mean tirzepatide is definitively better than semaglutide?
Read the original research
Head-to-head comparison of tirzepatide and semaglutide for weight loss: A systematic review and meta-analysis.
Obesity research & clinical practice
Citation
Zufry, Hendra; Hariyanto, Timotius Ivan. (2026). Head-to-head comparison of tirzepatide and semaglutide for weight loss: A systematic review and meta-analysis.. Obesity research & clinical practice. https://doi.org/10.1016/j.orcp.2026.02.002